Drug Trial Radar · NCT07213804
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,630
Planned (sponsor's estimate)
Start
Oct 22, 2025
Primary completion
Nov 2028
Study completion Aug 2031
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Asia-Pacific Gynecologic Oncology Trials Group
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.
Conditions
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Neoplasm Metastasis
Interventions
Sofetabart MipitecanDrug
Administered IV
PaclitaxelDrug
Administered IV
TopotecanDrug
Administered IV
GemcitabineDrug
Administered IV
Pegylated liposomal doxorubicin (PLD)Drug
Administered IV
MIRVDrug
Administered IV
BevacizumabDrug
Administered IV
CarboplatinDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by InvestigatorTime frame: Randomization to radiographic progression or death from any cause (up to 70 months)
- PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded, Independent, Central Review (BICR)Time frame: Randomization to radiographic progression or death from any cause (up to 70 months)
Locations
264 sites in 27 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Not yet recruiting
HonorHealth
Phoenix, Arizona · Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center
Burbank, California · Recruiting
City of Hope, Duarte
Duarte, California · Recruiting
City of Hope Lennar
Irvine, California · Recruiting
Kaiser Permanente Zion Medical Center
Irvine, California · Recruiting
Moores Cancer Center
La Jolla, California · Not yet recruiting
UCLA Hematology/Oncology - Westwood (Building 100)
Los Angeles, California · Recruiting
Stanford Women's Cancer Center
Palo Alto, California · Recruiting
Sansum Clinic
Santa Barbara, California · Recruiting
Kaiser Permanente
Vallejo, California · Not yet recruiting
Anschutz Cancer Pavilion
Aurora, Colorado · Recruiting
AdventHealth Medical Group - Porter
Denver, Colorado · Recruiting
UConn Health
Farmington, Connecticut · Recruiting
Broward Health Medical Center
Fort Lauderdale, Florida · Recruiting
Florida Cancer Specialist- South
Fort Myers, Florida · Recruiting
Baptist MD Anderson Cancer Center
Jacksonville, Florida · Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami, Florida · Recruiting
Mount Sinai Braman Comprehensive Cancer Center
Miami Beach, Florida · Recruiting
AdventHealth Orlando
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Not yet recruiting
Florida Cancer Specialist- East
West Palm Beach, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
Nancy N. & J.C. Lewis Cancer and Research Pavillion
Savannah, Georgia · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Not yet recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Rush University Medical Center
Chicago, Illinois · Not yet recruiting
The University of Chicago Medicine
Chicago, Illinois · Not yet recruiting
OSF Saint Fracis Medical Center
Peoria, Illinois · Recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Recruiting
Franciscan Health
Indianapolis, Indiana · Recruiting
Baptist Health Lexington
Lexington, Kentucky · Recruiting
University of Kentucky Chandler Medical Center
Lexington, Kentucky · Not yet recruiting
Norton Women's and Children's Hospital
Louisville, Kentucky · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Trials 365
Shreveport, Louisiana · Recruiting
Maine Medical Center - Scarborough Campus
Scarborough, Maine · Recruiting
Greater Baltimore Medical Center
Baltimore, Maryland · Recruiting
Sinai Hospital Of Baltimore
Baltimore, Maryland · Recruiting
Showing 40 of 264 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.